| [1] |
. Immunol Rev，2018，281（1）：154?168.
|
| [2] |
de la Fuente M，MacDonald TT，Hermoso MA. The IL-33/ST2 axis：role in health and disease［J］. Cytokine Growth Factor Rev，2015，26（6）：615?623.
|
| [3] |
Yang Y，Wang JB，Li YM，et al. Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma［J］. Oncol Lett，2016，12（1）：429?436.
|
| [4] |
Zhang P，Liu XK，Chu Z，et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications［J］. J Int Med Res，2012，40（5）：1654?1661.
|
| [5] |
Jin ZQ，Lei L，Lin DD，et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4+ and CD8+ T cell responses in hepatocellular carcinoma［J］. J Immunol，2018，201（12）：3770?3779.
|
| [6] |
Deng X，Xiong YQ，Ma B，et al. Expression of interleukin-33 in non-small cell lung cancer patients and its clinical significance［J］. Chin J Exp Surg（中华实验外科杂志），2016，33（4）：1122?1125.
|
| [7] |
Gao K，Li XY，Zhang L，et al. Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice［J］. Cancer Lett，2013，335（2）：463?471.
|
| [8] |
Deng KY，Wang H，Shan T，et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33［J］. Sci Rep，2016，6：24505.
|
| [9] |
Eissmann MF，Dijkstra C，Jarnicki A，et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization［J］. Nat Commun，2019，10（1）：2735.
|
| [10] |
Saranchova I，Han J，Huang H，et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33［J］. Sci Rep，2016，6：30555.
|
| [11] |
Zhou YX，Ji Y，Wang HG，et al. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L+ regulatory T cells in mice［J］. Technol Cancer Res Treat，2018，17：1533033818780091.
|
| [12] |
Zhang Y，Davis C，Shah S，et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis［J］. Mol Carcinog，2017，56（1）：272?287.
|
| [13] |
Xia YL，Ohno T，Nishii N，et al. Endogenous IL-33 exerts CD8+ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model［J］. Biochem Biophys Res Commun，2019，518（2）：331?336.
|
| [14] |
O''''Donnell C，Mahmoud A，Keane J，et al. An antitumorigenic role for the IL-33 receptor，ST2L，in colon cancer［J］. Br J Cancer，2016，114（1）：37?43.
|
| [15] |
Eissmann MF，Dijkstra C，Wouters MA，et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner［J］. Cancer Immunol Res，2018，6（4）：409?421.
|
| [16] |
Luo P，Deng SR，Ye H，et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling［J］. Biomed Pharmacother，2020，127：110232.
|
| [17] |
Gao Q，Han Y，Xu W，et al. Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models［J］. J China Pharm Univ（中国药科大学学报），2020，51（2）：206?212.
|
| [18] |
Deng SR，Deng Q，Zhang YJ，et al. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer［J］. Cancer Lett，2019，443：1?12.
|
| [19] |
Wang KL，Shan S，Yang ZJ，et al. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model［J］. Oncotarget，2017，8（40）：68571?68582.
|
| [20] |
Wang CH，Chen ZS，Bu XM，et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer［J］. Biochem Biophys Res Commun，2016，479（3）：461?468.
|
| [21] |
He ZX，Chen LL，Souto FO，et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice［J］. Sci Rep，2017，7（1）：5520.
|
| [22] |
Lu BF，Yang M，Wang QQ. Interleukin-33 in tumorigenesis，tumor immune evasion，and cancer immunotherapy［J］. J Mol Med，2016，94（5）：535?543.
|
| [23] |
Fournié JJ，Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity：a Yin and Yang cytokine［J］. Front Immunol，2018，9：2506.
|
百度学术
下载:
